Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation
Publikation: Beitrag in Fachzeitschrift › Forschungsartikel › Beigetragen › Begutachtung
Beitragende
Abstract
New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post-hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune dysregulation including autoimmune cytopenias. We describe an innovative therapy for AIHA refractory to proteasome inhibition. In potentially life-threatening AIHA in the context of HSCT, daratumumab may be an effective rescue therapy.
Details
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 2550-2553 |
Seitenumfang | 4 |
Fachzeitschrift | Blood advances |
Jahrgang | 2 |
Ausgabenummer | 19 |
Publikationsstatus | Veröffentlicht - 9 Okt. 2018 |
Peer-Review-Status | Ja |
Extern publiziert | Ja |
Externe IDs
PubMed | 30291113 |
---|---|
ORCID | /0009-0003-6519-0482/work/149439126 |